Chen, Branson
Lee, Jong Bok
Kang, Hyeonjeong
Minden, Mark D.
Zhang, Li
Funding for this research was provided by:
Canadian Cancer Society (704121)
Canadian Institutes of Health Research (141723)
Article History
Received: 1 March 2018
Accepted: 10 April 2018
First Online: 24 April 2018
Ethics approval and consent to participate
: Human blood samples were obtained from healthy adult donors and AML patients, respectively, after obtaining written informed consent and were used according to University Health Network Research Ethics Board (05–0221-T). Animal studies were approved by the institutional Animal Care Committee of the UHN (Permit Number: 741.35).
: LZ is a consultant for WYZE Biotech Co., Ltd. and one of three inventors of a patent for the method ofex vivoexpansion of human DNT cells and received license fees. LZ, JL and BC are inventors of a patent application using DNT cells to treat chemotherapy-resistant AML patients. The remaining authors declare no conflict of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.